| Literature DB >> 17970587 |
David M Good1, Visith Thongboonkerd, Jan Novak, Jean-Loup Bascands, Joost P Schanstra, Joshua J Coon, Anna Dominiczak, Harald Mischak.
Abstract
Sparked by the article from Lescuyer and colleagues in a recent issue, we aim here to further encourage interest in and discussion of clinically relevant biomarker research. We express our view on proteomics for biomarker discovery by addressing multiple relevant issues, including the inherent differences between biological fluids (and how these differences affect current analytical approaches) and experimental design to maximize the efficiency of moving from the bench to the bedside. Herein, we also include suggestions for definition of the term "biomarker", based on the use of a set of universal characterization/validation requirements, and illustrate several recent examples of successful transitions of benchtop proteomic studies work to clinical practice.Mesh:
Substances:
Year: 2007 PMID: 17970587 DOI: 10.1021/pr070529w
Source DB: PubMed Journal: J Proteome Res ISSN: 1535-3893 Impact factor: 4.466